<DOC>
	<DOCNO>NCT02529462</DOCNO>
	<brief_summary>This study evaluate efficacy NEUROPHARMAGEN pharmacogenetic test selection pharmacological treatment patient Major Depressive Disorder ( MDD ) , without psychiatric comorbidities . Patients randomly asigned test-guided treatment prescription treatment usual ina 1:1 ratio ; result test disclose later end 3-month follow-up period . The study compare rate treatment responder among group , base patient-reported improvement collect blind telephone interview .</brief_summary>
	<brief_title>Trial Evaluate Efficacy Pharmacogenetic Information Obtained With NEUROPHARMAGEN Treatment MDD Patients</brief_title>
	<detailed_description>NEUROPHARMAGEN genetic test develop AB-BIOTICS S.A. enable specific analysis Single-Nucleotide Polymorphisms related pharmacokinetics pharmacodynamics different psychoactive drug . The aim test provide psychiatrist information help him/her identify suitable medication patient . In study group , psychiatrist result NEUROPHARMAGEN test support information help him/her select best treatment patient . In control patient group , treatment select prescribed accordance routine clinical practice . This naturalistic , double-blind , randomize , multicentric clinicaltrial carry Spain psychiatry department several public hospital . The study aim include total 520 patient MDD , include patient significant psychiatric comorbidities anxiety substance abuse . The study compare group base rate treatment responder , define score 2 less ( i.e . `` Much good '' / '' Very much good '' ) Patient Global Impression Improvement scale ( PGI-I ) . This scale collect blind telephone interviewer , double-blind assessment ( patient interviewer ) .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Inclusion Criteria prerandomization visit : Patients diagnose major depressive disorder accord DSMIVTR criterion Patients give write informed consent participate study . In case disabled patient , inform consent legal representative responsible relative . Patients doctorrated Clinical Global Impression Severity Scale ( CGIS ) score equal great 4 . Patients diagnose de novo , doctor 's opinion , require medication receiving treatment require antidepressant , antipsychotic mood stabiliser replacement additional medication Exclusion Criteria prerandomization visit : Patients , investigator 's opinion , able complete study followup . Patients actively take part take part another clinical trial past 3 month . Patients pregnant breastfeeding , patient plan become pregnant within next 12 month . Patients require treatment quinidine , cinacalcet and/or terbinafine ( potent CYP2D6 inhibitor ) . Inclusion criterion randomization visit : Patients meet screen criterion prerandomisation visit must meet follow criterion visit 1 randomise . Otherwise , exclude active followup phase . The criterion : Patients PGII score 4 . Patients CGI score 4 . Patients whose dose pharmacological treatment , doctor 's opinion , require suppression , replacement , addition modification antidepressant , antipsychotic mood stabiliser .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>